Go Pro
NASDAQ:IVF

INVO Fertility Q2 2024 Earnings Report

INVO Fertility logo
$1.04 0.00 (0.00%)
Closing price 07/20/2026 04:00 PM Eastern
Extended Trading
$1.08 +0.04 (+4.33%)
As of 06:56 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

INVO Fertility EPS Results

Actual EPS
-$892.80
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

INVO Fertility Revenue Results

Actual Revenue
$1.84 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

INVO Fertility Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Wednesday, August 14, 2024
Conference Call Time
7:00AM ET

INVO Fertility Earnings Headlines

Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
See More INVO Fertility Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like INVO Fertility? Sign up for Earnings360's daily newsletter to receive timely earnings updates on INVO Fertility and other key companies, straight to your email.

About INVO Fertility

INVO Fertility (NASDAQ:IVF) (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation. By leveraging the natural conditions of the patient’s body, the INVOcell system aims to reduce the complexity, equipment requirements and cost associated with standard IVF lab procedures. INVO Fertility also provides complementary consumables and training programs to support fertility specialists in adopting its technology.

Originating in the early 2010s, INVO Fertility evolved from pioneering in-vivo fertilization research. The company secured U.S. Food and Drug Administration clearance for the INVOcell device in May 2015, marking a significant milestone that enabled commercial distribution. Since then, it has continued to expand its product portfolio and clinical support services to address the needs of fertility clinics and patients worldwide.

INVO Fertility markets and distributes its solutions across the United States and through a network of international partners in regions including Latin America, Europe, Asia-Pacific and the Middle East. The company collaborates with reproductive health professionals to provide hands-on training, technical assistance and ongoing clinical support, aiming to broaden access to cost-effective fertility treatment options globally.

View INVO Fertility Profile